` 2126 (JW (Cayman) Therapeutics Co Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2126
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, JW (Cayman) Therapeutics Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +51% compared to the Hang Seng (Hong Kong)'s +35% growth.

Stocks Performance
2126 vs Hang Seng (Hong Kong)

Loading
2126
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
2126 vs Hang Seng (Hong Kong)

Performance Gap Between 2126 and HSI
HIDDEN
Show

Performance By Year
2126 vs Hang Seng (Hong Kong)

Loading
2126
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
JW (Cayman) Therapeutics Co Ltd vs Peers

Hang Seng (Hong Kong)
2126
ABBV
AMGN
GILD
VRTX
Add Stock

JW (Cayman) Therapeutics Co Ltd
Glance View

Market Cap
1.2B HKD
Industry
Biotechnology

JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.

JW (Cayman) Therapeutics Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top